Novo Ventures

Portfolio Co Investors 2026 for Novo Ventures: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Novo Ventures accounts for 10 tracked companies with verified cap-table data, 10 of which disclose round sizes totalling $1.6B. The median disclosed raise is $154M, and the largest is Nkarta Therapeutics at $404M, ahead of Unchained Labs ($250M) and Amolyt Pharma ($210M).

The names that recur most often on these co-invested cap tables are Novo Ventures (10 companies), Novo Holdings (2 companies), Pfizer (2 companies), Sanofi Ventures (2 companies), SR One (1 company), NEA (1 company). By latest disclosed round, the market skews IPO (2), Series C (2), Series B (2), Series A (2).

Best funded Novo Ventures companies

  1. Nkarta Therapeutics — $404M (latest: IPO)
  2. Unchained Labs — $250M (latest: Growth)
  3. Amolyt Pharma — $210M (latest: Series C)
  4. Anokion — $160M (latest: Series B)
  5. ReViral — $154M (latest: IPO)
  6. INBRACE — $127M (latest: Series D)
  7. Inozyme — $116M (latest: Series A)
  8. Reneo Pharmaceuticals — $95M (latest: Series B)
  9. Lava Therapeutics — $83M (latest: Series C)
  10. Allakos — $32M (latest: Series A)

Novo Ventures — related firms and companies (53)

Novo Ventures alternatives · All research reports